单中心随机试验:单纯T-reg移植物对比T-reg移植物联合他克莫司预防急性GVHD
这项开放标签单中心2期研究第一阶段将24例接受清髓性HLA相合或9/10相合造血干细胞移植的患者随机分为单纯T-reg移植物组(n=12)或T-reg移植物联合单药GVHD预防组(n=12),比较急性GVHD预防效果。结果显示单纯T-reg移植物组3-4级急性GVHD发生率为58% vs 联合组8%(P=.005),3-4级为17% vs 0%(P=.149),中重度慢性GVHD为28% vs 0%(P=.056)。研究表明联合单药他克莫司优于单纯T-reg移植物。
要点
- 单纯T-reg移植物组3-4级急性GVHD发生率为58%,联合他克莫司组为8%(P=.005)。
- 单纯T-reg移植物组3-4级急性GVHD发生率为17%,联合组为0%(P=.149)。
- 中重度慢性GVHD发生率单纯组为28%,联合组为0%(P=.056)。
核心结论
- 本研究表明,在预防急性GVHD方面,T-reg移植物联合单药他克莫司优于单纯T-reg移植物。
研究设计与样本
- 开放标签单中心2期研究(NCT01660607)第一阶段,纳入接受清髓性HCT的HLA相合及9/10相合受者。
- 24例患者随机接受单纯T-reg移植物(n=12)或T-reg移植物联合单药GVHD预防(n=12),以判断单纯T-reg移植物预防急性GVHD是否非劣效。
- T-reg移植物为定时序贯输注CD34+造血干细胞和高纯度Tregs后再输注常规T细胞。
主要发现
- 所有患者均达到完全供者髓系嵌合。
- 单纯T-reg移植物组 vs 联合预防组3-4级急性GVHD发生率为58% vs 8%(P=.005)。
- 单纯T-reg移植物组 vs 联合预防组3-4级急性GVHD发生率为17% vs 0%(P=.149)。
- 中重度慢性GVHD发生率单纯T-reg移植物组为28% vs 联合预防组0%(P=.056)。
- 联合预防组移植后CD4+ T细胞与Treg比值降低,基因表达谱显示CD4+增殖减少,完全供者T细胞嵌合达成延迟。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Allogeneic hematopoietic cell transplantation (HCT) is a curative therapy for hematological malignancies for which graft-versus-host disease (GVHD) remains a major complication. The use of donor T-regulatory cells (Tregs) to prevent GVHD appears promising, including in our previous evaluation of an engineered graft product (T-reg graft) consisting of the timed, sequential infusion of CD34+ hematopoietic stem cells and high-purity Tregs followed by conventional T cells. However, whether immunosuppressive prophylaxis can be removed from this protocol remains unclear. We report the results of the first stage of an open-label single-center phase 2 study (NCT01660607) investigating T-reg graft in myeloablative HCT of HLA-matched and 9/10-matched recipients. Twenty-four patients were randomized to receive T-reg graft alone (n = 12) or T-reg graft plus single-agent GVHD prophylaxis (n = 12) to determine whether T-reg graft alone was noninferior in preventing acute GVHD. All patients developed full-donor myeloid chimerism. Patients with T-reg graft alone vs with prophylaxis had incidences of grade 3 to 4 acute GVHD of 58% vs 8% (P = .005) and grade 3 to 4 of 17% vs 0% (P = .149), respectively. The incidence of moderate-to-severe chronic GVHD was 28% in the T-reg graft alone arm vs 0% with prophylaxis (P = .056). Among patients with T-reg graft and prophylaxis, CD4+ T-cell-to-Treg ratios were reduced after transplantation, gene expression profiles showed reduced CD4+ proliferation, and the achievement of full-donor T-cell chimerism was delayed. This study indicates that T-reg graft with single-agent tacrolimus is preferred over T-reg graft alone for the prevention of acute GVHD. This trial was registered at www.clinicaltrials.gov as #NCT01660607.
引用
- Bader CS, Pavlova A, Lowsky R, et al. Single-center randomized trial of T-reg graft alone vs T-reg graft plus tacrolimus for the prevention of acute GVHD. Blood Adv. 2024. PMID: 38091578. doi:10.1182/bloodadvances.2023011625
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。